29 Jan, 2012
Ranbaxy's recurring FDA nightmare
The company has to give up 180-day marketing exclusivity rights for three generic drugs where it has the first-to-file (FTF) status
Source: Livemint.com
Company:
RANBAXY LAB.
Corporate News Headlines for Indian Investors
Useful Links
- Moneycontrol.com
- Download MProfit - Portfolio Management Software
- Livemint
- BSE Top Gainers
- BSE Top Losers
- BSE Corporate Announcements
- Bombay Stock Exchange
- NSE India
- NDTV Profit
- IndiaEarnings.com
- Financial Express
- Hindu - Business Line
- DNA Money
- Business Standard
- UTVi.com
- The Economic Times
- Bloomberg India News
- ICICI Direct
- Value Notes
- Yahoo India Finance
- Personalfn
- Equitymaster
- Capital Market
- Value Research
Recent Headlines
- Arshiya Rail, GATX India ink pact to lease rakes
- Tech Mahindra Q4 reported PAT seen up 15% at Rs 318 cr
- Rural Electrification Corp Q4 PAT seen up 9% at Rs 760 Cr
- Opto Circuits Q4 beats estimates, PAT up 88% to Rs 209 cr
- After Airtel, other telcos eye lower 3G tariffs
- Vodafone India IPO unlikely in 2012 if spectrum proposals accepted
- Tata Comm Q4 consolidated loss widens
- Negative on ADAG stocks, buy Tata Power at Rs 85: Tulsian
- Post offices will collect Airtel bills in Chennai
- MphasiS wins insurance deal from Willamette